Genomic News and Research

RSS

IDT opens molecular biology R&D facility in Redwood City

Already the world’s leader in custom nucleic acid synthesis, Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. Research and development for these products will now be performed in a newly built facility in Redwood City, California.

From Integrated DNA Technologies 28 Apr 2015

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex Corporation today announced that testing at the clinical trial sites for the ARIES HSV 1&2 Assay is now complete. The next steps, including site to site reproducibility testing, followed by data analysis and assembly of the data package for submission to the FDA, are now underway.

From Luminex 28 Apr 2015

PCDx test performs better than FoundationOne test in clinical study

Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine's FoundationOne test across a number of key clinical variables, including turnaround time (TAT) and clinically actionable biomarker targets.

28 Apr 2015

Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.

27 Apr 2015

Common diabetes medication causes intersex in fish

A medication commonly taken for Type II diabetes, which is being found in freshwater systems worldwide, has been shown to cause intersex in fish -male fish that produce eggs.

27 Apr 2015

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling.

25 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

EMD Millipore launches Magna ChIRP RNA Interactome Kits for analyzing chromatin-associated RNAs

EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today introduced Magna ChIRP™ RNA Interactome Kits, which allow researchers to more easily identify, recover and analyze regions of chromatin that interact with chromatin-associated RNAs such as long non-coding RNA (lncRNA).

23 Apr 2015

Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

A new study presented today at The International Liver Congress 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments.

23 Apr 2015

ADCs based on alpha-amanatin may help treat colorectal cancer

For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.

23 Apr 2015

UC San Diego, Scripps partner to improve patient care, physician training and research in hospice medicine

UC San Diego Health System and Scripps Health are partnering to provide improved continuity of patient care, fellowship training and research in hospice and palliative medicine. Under a new five-year agreement, Scripps will work with UC San Diego to provide outpatient and inpatient hospice care for UC San Diego patients, allowing UC San Diego physicians to better coordinate post-acute care for patients with chronic illness.

23 Apr 2015

New class of drugs targeting blood glucose level could benefit individuals with type 2 diabetes

Individuals with type 2 diabetes, who are resistant to insulin, have an excess blood glucose level, which they are now trying to reduce using a new class of diabetes drugs known as the gliflozins.

22 Apr 2015

Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from treatment with the pioneering drug olaparib - the first cancer drug to target inherited mutations - according to the results of a major trial presented today (Tuesday).

22 Apr 2015

SQream Technologies releases GenomeStack platform for genome research

SQream Technologies, provider of the world's fastest big data analytics database, today announced the release of GenomeStack, its latest innovative platform developed specifically for genome research.

21 Apr 2015

New clinical utility data for Guardant360 platform to be presented at 2015 AACR Annual Meeting

Guardant Health today announced new clinical utility data for its Guardant360 platform, which will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia.

21 Apr 2015

New CUMC study finds DNA anomalies in kids with chronic kidney disease

A significant proportion of children with chronic kidney disease (CKD) have unsuspected chromosomal imbalances, including DNA anomalies that have been linked to neurocognitive disorders, according to a new Columbia University Medical Center study.

21 Apr 2015

New collaboration brings comprehensive genomic profiling to UC Davis

The UC Davis Comprehensive Cancer Center and the Department of Pathology and Laboratory Medicine have entered into a collaboration with Foundation Medicine, a leading molecular information company. The collaboration brings comprehensive genomic profiling into standard of care at UC Davis, allowing physicians to prescribe the most effective, targeted cancer treatments to patients based on the genomic information specific to each individual's cancer.

21 Apr 2015

Global changes in cancer cells' epigenome may determine disease progression

Genomic studies have illuminated the ways in which malfunctioning genes can drive cancer growth while stunting the therapeutic effects of chemotherapy and other treatments. But new findings from Weill Cornell Medical College investigators indicate that these genes are only partly to blame for why treatment that was at one point effective ultimately fails for about 40 percent of patients diagnosed with the most common form of non-Hodgkin Lymphoma.

21 Apr 2015

Latest genome sequencing techniques help identify new autoimmune syndrome in children

Using the latest genome sequencing techniques, a research team led by scientists from UC San Francisco, Baylor College of Medicine, and Texas Children's Hospital has identified a new autoimmune syndrome characterized by a combination of severe lung disease and arthritis that currently has no therapy.

21 Apr 2015

AACR throws spotlight on the experience of Individualized Molecular Pancreatic Cancer Therapy trial

After performing thousands of unsuccessful experiments in his attempt to perfect the light bulb, Thomas Edison famously remarked: "I have not failed, not once. I've discovered ten thousand ways that don't work."

21 Apr 2015